Accelerated drug discovery powered by nature
Pangea Botanica brings the platform business model of company building to nature-inspired drug discovery and development
Our mission is to accelerate the discovery and development of therapeutics inspired by naturally-occurring molecules and traditional remedies, while preserving ethnobotanical knowledge and ecosystems.
Accelerated drug discovery
Pangea brings a higher likelihood of success and reduced timeline in developing new medicines for patients. We optimise our success rates and development time by focusing on nature-inspired compounds with prior evidence of safety and efficacy.
Our platform operating model enables us to develop multiple products and indications, in an efficient and scalable way. We already have four drug development operating companies, targeting auto-immune, psychiatric, neurodegenerative and neurological indications. Click here for more information on our first operating company, Kanna Health.
Our team has a track record of building companies around natural products and biotech platforms - at COMPASS Pathways (Nasdaq: CMPS); GW Pharmaceuticals (acquired by Jazz Pharmaceuticals); and atai Life Sciences (Nasdaq: ATAI).
Preservation and positive impact
We are committed to preserving ethnobotanical knowledge and habitats, and supporting the communities from which our compounds are derived.
We want to have a lasting and positive impact on local communities and the environment, as well as on patients, and are applying for B Corp certification.
Significant untapped potential in nature-inspired drug development
of today's small molecules are nature-inspired
of plant species still
of nature-derived therapeutics have an ethnomedical use identical or related to the current use